March 27, 2018 / 11:21 AM / a month ago

BRIEF-Itus And Serametrix Announce Results Of A Blinded Prostate Cancer Study

March 27 (Reuters) - Itus Corp:

* ITUS AND SERAMETRIX ANNOUNCE RESULTS OF A BLINDED PROSTATE CANCER STUDY

* ITUS- ALONG WITH SERAMETRIX, CO EVALUATING WHETHER CCHEK MAY BE UTILIZED TO DISTINGUISH BETWEEN RESPONDERS AND NON-RESPONDERS TO IMMUNE-THERAPIES

* ITUS CORP - ITUS CORRECTLY IDENTIFIED 33 OF 36 PROSTATE CANCER SAMPLES AND 34 OF 37 HEALTHY DONOR SAMPLES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below